Efficacy News and Research

RSS

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

Opisthorchis viverrini is a parasitic flatworm (or liver fluke) endemic throughout Thailand, the Lao People’s Democratic Republic, Vietnam and Cambodia. Humans are infected with this parasite when they eat a fluke encysted in inadequately cooked/preserved freshwater fish.

21 Sep 2014

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

21 Sep 2014

Viewpoints: Many beneficiaries of health law don't vote; reboot for healthcare.gov

For starters, my strong hunch from my own reporting in the region over the past couple years - including several trips to Kentucky for a new book on McConnell - is that the Democrats' biggest problem in Appalachia and the Upland South is not that the people who are benefitting from Obamacare or would stand to benefit from it if their states fully implemented the law are voting against their own interests, for Republicans.

19 Sep 2014

Amedica releases Valeo II TL silicon nitride interbody fusion devices

Amedica Corporation, a commercial biomaterial company focused on silicon nitride ceramics as a material platform to develop, manufacture and sell novel medical devices, is pleased to announce the release of its second generation silicon nitride transforaminal lumbar (TL) interbody fusion device.

19 Sep 2014

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Lack of sleep can make you sick. And while everybody has the occasional restless night, for those who suffer from chronic insomnia — some 15 percent of older adults in the United States — that sleep loss can increase the risk for cardiovascular disease, hypertension, weight gain, type 2 diabetes, and even lead to an earlier death.

18 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease.

18 Sep 2014

Magnetic resonance: A good method for detecting and quantifying fats in the liver

Obesity and overweight affect more than half of the population in our Community. Excess weight causes important alterations in the organism, one of which affects liver function. Fat accumulates in the liver producing hepatic steatosis which, in certain circumstances, causes inflammation, fibrosis and finally, cirrhosis.

18 Sep 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Sacral neuromodulation augments efficacy of antimuscarinics in OAB

The addition of sacral neuromodulation to antimuscarinic pharmacotherapy offers significant benefits over antimuscarinics alone in the treatment of women with idiopathic overactive bladder, study findings show.

17 Sep 2014

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found.

17 Sep 2014

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and anatomic segmentectomy appear to offer similar perioperative and oncological outcomes in patients with stage I non-small-cell lung cancer, analysis suggests.

17 Sep 2014

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Isis Pharmaceuticals, Inc. announced that it has earned a $4 million milestone payment from Achaogen, Inc. associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.

17 Sep 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Covidien begins enrollment in two clinical trials for advanced neurovascular solutions

Covidien plc announced today the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions.

16 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Efficacy News and Research

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

Viewpoints: Many beneficiaries of health law don't vote; reboot for healthcare.gov

Amedica releases Valeo II TL silicon nitride interbody fusion devices

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Magnetic resonance: A good method for detecting and quantifying fats in the liver

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

Ramucirumab effective second-line option for NSCLC

Sacral neuromodulation augments efficacy of antimuscarinics in OAB

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Covidien begins enrollment in two clinical trials for advanced neurovascular solutions

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News